Why the study?
Does the addition of trimetazidine to standard therapy improve exercise tolerance and quality of life in patients with ischemic heart disease?
Does the addition of trimetazidine to standard therapy improve exercise tolerance and quality of life in patients with ischemic heart disease?
Trimetazidine added to standard therapy provides significant antianginal benefits and improves exercise tolerance in patients with ischemic heart disease.
May support trimetazidine as IHD adjunct; hypothesis-generating from Level 5 review, RCTs needed before practice change.
Meta-analytic data shows that addition of trimetazidine (TMZ) to standard therapy increases significantly exercise tolerance in ischemic heart disease (IHD) patients. In heart failure due to IHD, condition improves as well, administering TMZ. There is no strict evidence that TMZ is especially effective in people with comorbid diabetes. TMZ shows significant antianginal effect in combination with other medications that is, certainly, improves life quality of patients.
No takes yet. Share an insight, caveat, or question.
V. P. Lupanov (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: